The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study.
Litong YaoZhiyuan PangMozhi WangMengshen WangXiangyu SunMingke CuiYanfu ZhengXinyan LiHaoran DongQiang ZhangYingying XuPublished in: Cancer biology & medicine (2021)
Standard NAC cycles were associated with a significant survival benefit, especially in patients with HER2 positive or triple negative breast cancer.